Preston C. Sprenkle, MD
Research & Publications
Biography
News
Research Summary
Integration of prostate imaging and genomics for more personalized diagnosis and treatment of prostate cancers. collaborate with translational scientists and machine learning specialists to develop predictive models utilizing multiple clinical factors to improve diagnostic predictions and modeling.
Extensive Research Description
Improving accuracy of prostate cancer diagnosis, staging, and treatment through enhanced imaging techniques with Prostate MRI and targeted prostate biopsies using our clinical outcomes database.
Clinical trial interventions on patients with high risk prostate cancer as well as utilizing new techniques and technologies for ablation (destruction) of prostate cancer using such technologies as cryoablation, irreversible electroporation, TULSA, laser ablation, and others.
Coauthors
Research Interests
Magnetic Resonance Imaging; Prostatectomy; Urology; Genomics; Ablation Techniques; High-Intensity Focused Ultrasound Ablation; Machine Learning
Selected Publications
- Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate BiopsyDiaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 1-10. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.
- Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data LinkageLeapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.
- MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?Webb L, Diaz G, Rahman S, Khajir G, Sprenkle P. MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE? Journal Of Urology 2024, 211: e504. DOI: 10.1097/01.ju.0001008936.35187.0b.04.
- MP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRIDiaz G, Webb L, Khajir G, Sprenkle P. MP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRI. Journal Of Urology 2024, 211: e313. DOI: 10.1097/01.ju.0001008716.22569.77.09.
- MP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORTShumaker L, Fang A, Kaneko M, Ramacciotti L, Prakash N, Das A, Patel H, Khajir G, Fan R, Wang S, Pineault K, Sidana A, Gupta G, Filson C, Wysock J, Siddiqui M, Sonn G, Sprenkle P, Ross A, Jarrard D, Punnen S, Abreu A, Rais-Bahrami S. MP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORT. Journal Of Urology 2024, 211: e316. DOI: 10.1097/01.ju.0001008716.22569.77.16.
- PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATESLeapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.
- MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSYWebb L, Diaz G, Velasquez E, Goberdhan S, Khajir G, Sundaresan V, Leapman M, Sprenkle P. MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY. Journal Of Urology 2024, 211: e315. DOI: 10.1097/01.ju.0001008716.22569.77.12.
- MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEMKunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.
- PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDYLeapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.
- PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELINGKunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.
- A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative studyLokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Brito J, Renzulli J, Sprenkle P, Michael M. A0305 Pathologic gleason upgrading following high-resolution micro-ultrasound, conventional ultrasound and MRI fusion biopsy techniques: A comparative study. European Urology 2024, 85: s1101. DOI: 10.1016/s0302-2838(24)00884-4.
- RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRISundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.
- Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy HistopathologyZeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.
- Association Between Pelvic Lymph Node Dissection and Survival Among Patients with Prostate Cancer Treated with Radical ProstatectomyKim I, Wang A, Corpuz G, Sprenkle P, Leapman M, Brito J, Renzulli J, Kim I. Association Between Pelvic Lymph Node Dissection and Survival Among Patients with Prostate Cancer Treated with Radical Prostatectomy. Prostate International 2024 DOI: 10.1016/j.prnil.2024.01.002.
- Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.
- Association between sociodemographic factors and diagnosis of lethal prostate cancer in early lifeSmani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.
- Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐upKhajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.
- Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsyKhajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.
- MP59-12 CAN ANATOMICAL MEASUREMENTS ON PREOPERATIVE PELVIC MAGNETIC RESONANCE IMAGING PREDICT POSTOPERATIVE URINARY INCONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE?Khan A, Choksi A, Rahman S, Press B, Jalfon M, Gardezi M, Jones T, Hayden C, Ghiraldi E, Siev M, Lacy G, Sprenkle P, Kellner D. MP59-12 CAN ANATOMICAL MEASUREMENTS ON PREOPERATIVE PELVIC MAGNETIC RESONANCE IMAGING PREDICT POSTOPERATIVE URINARY INCONTINENCE AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE? Journal Of Urology 2023, 209: e812. DOI: 10.1097/ju.0000000000003312.12.
- MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFESmani S, Novosel M, Marks V, Jeong F, Sprenkle P, Leapman M. MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE. Journal Of Urology 2023, 209: e1079. DOI: 10.1097/ju.0000000000003349.01.
- PD20-07 ASSOCIATIONS BETWEEN PATIENT SOCIODEMOGRAPHIC FACTORS AND RISK-APPROPRIATE PROSTATE CANCER MANAGEMENTNovosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. PD20-07 ASSOCIATIONS BETWEEN PATIENT SOCIODEMOGRAPHIC FACTORS AND RISK-APPROPRIATE PROSTATE CANCER MANAGEMENT. Journal Of Urology 2023, 209: e586. DOI: 10.1097/ju.0000000000003286.07.
- PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCERLeapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.
- MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGELeapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Ross A, Sprenkle P. MP17-09 DEVELOPMENT OF A LONGITUDINAL PROSTATE CANCER TRANSCRIPTOMIC AND REAL-WORLD CLINICAL DATA LINKAGE. Journal Of Urology 2023, 209: e216. DOI: 10.1097/ju.0000000000003237.09.
- MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASETLeapman M, Ho J, Liu Y, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Spratt D, Cooperberg M, Sprenkle P, Ross A. MP17-02 ASSOCIATION BETWEEN THE DECIPHER GENOMIC CLASSIFIER AND PROSTATE CANCER OUTCOME IN A LARGE-SCALE REAL-WORLD DATASET. Journal Of Urology 2023, 209: e212. DOI: 10.1097/ju.0000000000003237.02.
- PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNINGEsmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
- NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.Moses K, Sprenkle P, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 236-246. PMID: 36898362, DOI: 10.6004/jnccn.2023.0014.
- Abstract No. 160 MR Susceptibility-Weighted Imaging During Transurethral Prostate Sono-Ablation Procedures for Guidance of Device Placement to Counter Effect of Intra-Prostatic CalcificationsLee J, Ghanouni P, Costa D, Shin C, Khalighinejad P, Sprenkle P, Staruch R, Beserra A, Arora S. Abstract No. 160 MR Susceptibility-Weighted Imaging During Transurethral Prostate Sono-Ablation Procedures for Guidance of Device Placement to Counter Effect of Intra-Prostatic Calcifications. Journal Of Vascular And Interventional Radiology 2023, 34: s74-s75. DOI: 10.1016/j.jvir.2022.12.214.
- Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life.Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.
- Associations between patient sociodemographic factors and non-treatment for localized prostate cancer.Novosel M, Smani S, Marks V, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. Journal Of Clinical Oncology 2023, 41: 307-307. DOI: 10.1200/jco.2023.41.6_suppl.307.
- Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.
- Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesionsFang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.
- Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancerLokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.
- PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIESKhajir G, Press B, Sprenkle P, Washington S, Cooperberg M, Leapman M. PD41-04 DISTRIBUTION OF NATIONAL COMPREHENSIVE CANCER NETWORK RISK CLASSIFICATIONS USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION VERSUS SYSTEMIC 12 CORE BIOPSIES. Journal Of Urology 2022, 207: e690. DOI: 10.1097/ju.0000000000002602.04.
- MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMYKhajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.
- PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONSFang A, Shumaker L, Martin K, Onah O, Jackson J, Khajir G, Fan R, Soodana-Prakash N, Patel H, Vourganti S, Filson C, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2022, 207: e959. DOI: 10.1097/ju.0000000000002637.01.
- MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENINGLeapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Journal Of Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
- Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.
- Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate CancerBuck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.
- MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONSFang A, Shumaker L, Khajir G, Fan R, Soodana-Prakash N, Patel H, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2021, 206: e78-e78. DOI: 10.1097/ju.0000000000001972.05.
- MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSYPress B, Khajir G, Olawoyin O, Leapman M, Sprenkle P. MP26-14 RISK STRATIFICATION BY PROSTATE HEALTH INDEX PRIOR TO MRI-ULTRASOUND FUSION TARGETED BIOPSY. Journal Of Urology 2021, 206: e468-e468. DOI: 10.1097/ju.0000000000002023.14.
- Benign and Malignant Diseases of the ProstateSyed J, Sprenkle P. Benign and Malignant Diseases of the Prostate. 2020, 651-682. DOI: 10.1007/978-3-319-47771-8_79.
- PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomyAbello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy. European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
- PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIALSprenkle* P, Carroll P, Probst S, Gorin M, Rowe S, Pienta K, Pouliot F, Patnaik A, Preston M, Alva A, Siegel B, Morris M. PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.05.
- MP23-11 PREDICTION OF ADVERSE OUTCOMES AT RADICAL PROSTATECTOMY IN GRADE GROUP 2 AND 3 PROSTATE BIOPSIES USING MACHINE LEARNINGPaulson* N, Zeevi T, Papademetris M, Onofrey J, Sprenkle P, Humphrey P, Staib L, Levi A. MP23-11 PREDICTION OF ADVERSE OUTCOMES AT RADICAL PROSTATECTOMY IN GRADE GROUP 2 AND 3 PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000856.011.
- MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMYAbello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY. Journal Of Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
- Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.
- Benign and Malignant Diseases of the ProstateSyed J, Sprenkle P. Benign and Malignant Diseases of the Prostate. 2019, 1-32. DOI: 10.1007/978-3-319-20317-1_79-1.
- P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate CancerYang D, Yu J, An Y, Sprenkle P, Leapman M, Park H. P28 Rectal Radiation Dose Comparison Between Definitive Radiotherapy with Hydrogel Spacer Injection versus Post-prostatectomy Radiotherapy for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e33. DOI: 10.1016/s0360-3016(19)30478-x.
- PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, Sprenkle P. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.
- FR02-04 UROLOGIC HEALTH THROUGHOUT THE HISTORY OF THE WHITE HOUSEAmirkhiz* K, Goland-Van Ryn M, Motamedinia P, Leapman M, Sprenkle P, Weiss R. FR02-04 UROLOGIC HEALTH THROUGHOUT THE HISTORY OF THE WHITE HOUSE. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555417.67392.ee.
- PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCERAbello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
- PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDERJavier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
- MP01-20 THE LEARNING CURVE FOR MULTI-PARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCELeung C, Syed J, Pan S, Neville T, Sprenkle P. MP01-20 THE LEARNING CURVE FOR MULTI-PARAMETRIC MRI/US FUSION GUIDED PROSTATE BIOPSY: A SINGLE CENTER EXPERIENCE. Journal Of Urology 2018, 199: e11. DOI: 10.1016/j.juro.2018.02.126.
- MP77-19 CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MENWang N, Fan R, Sprenkle P, Sonn G. MP77-19 CLINICAL TOOL PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN. Journal Of Urology 2018, 199: e1035. DOI: 10.1016/j.juro.2018.02.2607.
- MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMYAmirkhiz K, Suarez-Sarmiento A, Nguyen K, Hsiang W, Amalraj S, Syed J, Leapman M, Schulam P, Sprenkle P. MP53-10 ASSOCIATION OF SYSTEMATIC BIOPSY VS. MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION TARGETED BIOPSY WITH PROSTATE CANCER UPSTAGING AT RADICAL PROSTATECTOMY. Journal Of Urology 2018, 199: e707-e708. DOI: 10.1016/j.juro.2018.02.1681.
- MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY?Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Journal Of Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.
- MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCEHsiang W, Ghabili K, Lu A, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. MP17-12 UTILITY OF SERIAL MRI/ULTRASOUND FUSION TARGETED BIOPSY IN MEN WITH LOW RISK PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE. Journal Of Urology 2018, 199: e209. DOI: 10.1016/j.juro.2018.02.567.
- Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions.Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.
- Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.
- How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.
- Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.
- The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men.Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.
- Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case reportNguyen K, Nawaf C, Levi A, Huber S, Lu A, Say R, Sprenkle P. Bacillus Calmette–Guérin therapy-induced granulomatous prostatitis on multiparametric magnetic resonance imaging: a case report. Journal Of Clinical Urology 2016, 10: 280-282. DOI: 10.1177/2051415816651561.
- PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS?Lu A, Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS? Journal Of Urology 2016, 195: e393. DOI: 10.1016/j.juro.2016.02.1137.
- MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCERNawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. MP15-17 MP-MRI UPGRADES MEN WHO HAVE HAD A BIOPSY SHOWING PRIOR CANCER. Journal Of Urology 2016, 195: e158. DOI: 10.1016/j.juro.2016.02.2541.
- Decision forests for learning prostate cancer probability maps from multiparametric MRIEhrenberg H, Cornfeld D, Nawaf C, Sprenkle P, Duncan J. Decision forests for learning prostate cancer probability maps from multiparametric MRI. Proceedings Of SPIE--the International Society For Optical Engineering 2016, 9785: 97851j-97851j-14. DOI: 10.1117/12.2216904.
- MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.
- MRI-US fusion targeted biopsy results in men with a history of prior cancer.Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.
- MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.
- Prostate cancer detection rates of negative MP-MRIs.Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.
- MP86-08 CONFIRMATION: ANALYSIS OF PSA TRENDS HELPS IDENTIFY DEADLY PROSTATE CANCERS PRIOR TO BIOPSYKarnes R, Loeb S, Sprenkle P, Morrell C, MacKintosh F, Rawson L, Neville T. MP86-08 CONFIRMATION: ANALYSIS OF PSA TRENDS HELPS IDENTIFY DEADLY PROSTATE CANCERS PRIOR TO BIOPSY. Journal Of Urology 2015, 193: e1078-e1079. DOI: 10.1016/j.juro.2015.02.1917.
- MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALEKardos S, Pan S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. MP17-08 MRI-FUSION PROSTATE BIOPSY IN FIRST-TIME BIOPSY COHORT YIELDS INCREASED DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER USING A SIMPLIFIED MRI GRADING SCALE. Journal Of Urology 2015, 193: e179. DOI: 10.1016/j.juro.2015.02.850.
- Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy.Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.
- Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship?Sprenkle P, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Benson M, Rutman M. Exploring medical student education initiatives: does the management of urologic conditions improve with a formal urology clinical clerkship? Journal Of Medicine And The Person 2011, 9: 116-122. DOI: 10.1007/s12682-011-0101-y.
- 1269 OUTCOMES FOLLOWING RENAL SURGERY IN HIGH-RISK PATIENTS: A NON-RANDOMIZED COMPARISON OF OPEN AND MINIMALLY INVASIVE SURGICAL APPROACHESSprenkle P, Sankin A, Savage C, Musser J, Touijer K, Russo P, Coleman J. 1269 OUTCOMES FOLLOWING RENAL SURGERY IN HIGH-RISK PATIENTS: A NON-RANDOMIZED COMPARISON OF OPEN AND MINIMALLY INVASIVE SURGICAL APPROACHES. Journal Of Urology 2011, 185: e507. DOI: 10.1016/j.juro.2011.02.954.
- COMPARISON OF COMPLETE INTRACORPOREAL CONSTRUCTION OF AN ILEUM NEOBLADDER UTILIZING STANDARD SUTURED TECHNIQUES AND NOVEL TECHNOLOGIESHruby G, Sprenkle P, Lehman D, Durak E, Marruffo F, Mirabile G, McKiernan J, Gupta M, Landman J. COMPARISON OF COMPLETE INTRACORPOREAL CONSTRUCTION OF AN ILEUM NEOBLADDER UTILIZING STANDARD SUTURED TECHNIQUES AND NOVEL TECHNOLOGIES. Journal Of Urology 2008, 179: 248. DOI: 10.1016/s0022-5347(08)60716-8.
- THE EFFECT OF ARGON GAS PRESSURE ON ICE BALL SIZE AND RATE OF FORMATIONSprenkle P, Mirabile G, Hruby G, Phillips C, Xavier K, Gupta M, Landman J. THE EFFECT OF ARGON GAS PRESSURE ON ICE BALL SIZE AND RATE OF FORMATION. Journal Of Urology 2008, 179: 243-244. DOI: 10.1016/s0022-5347(08)60703-x.
- High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomyPierorazio P, Lambert S, Matsukhani M, Sprenkle P, McCann T, Katz A, Olsson C, Benson M, McKiernan J. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. BJU International 2007, 0: 070907021207002-???. DOI: 10.1111/j.1464-410x.2007.07115.x.
- Benign prostate hyperplasia in the older maleSprenkle P, Lowe F. Benign prostate hyperplasia in the older male. Aging Health 2007, 3: 177-189. DOI: 10.2217/1745509x.3.2.177.
- 578: Distal Ureteral Morphogenesis Depends on Apoptosis Induced by Signals from the Urogenital Sinus: A New Model of Ureteral MaturationLambert S, Batourina E, Tsai S, Viana R, Sprenkle P, Dutta S, Hensle T, Mendelsohn C. 578: Distal Ureteral Morphogenesis Depends on Apoptosis Induced by Signals from the Urogenital Sinus: A New Model of Ureteral Maturation. Journal Of Urology 2006, 175: 187-188. DOI: 10.1016/s0022-5347(18)32824-6.
- 1717: The Bladder Trigone is not a Wolffian Duct RemnantSprenkle P, Batourina E, Tsai S, Lambert S, Paragas N, Glassberg K, Hensle T, Mendelsohn C. 1717: The Bladder Trigone is not a Wolffian Duct Remnant. Journal Of Urology 2004, 171: 454. DOI: 10.1016/s0022-5347(18)38909-2.